Skip to main content
Premium Trial:

Request an Annual Quote

ProGenetics to Distribute Oncocyte Lung Cancer Test in Israel

NEW YORK – Oncocyte said on Thursday that it has entered a distribution agreement with ProGenetics, expanding the commercial availability of its DetermaRx test to Israel. Financial and other terms were not disclosed.

DetermaRx is a treatment stratification test that identifies patients at high risk for lung cancer recurrence who may benefit from adjuvant chemotherapy after tumor removal surgery. Oncocyte launched the test in the United States through an early-access program in late January, which it said has now expanded to over 40 sites.

The distribution agreement with ProGenetics is Oncocyte's second this year, following a deal with Core Diagnostics in April to make DetermaRx available in India, the Middle East, and Africa.

In a statement, Oncocyte CEO Ron Andrews said that ProGenetics is a welcome partner in growing the reach of DetermaRx globally. "International expansion is central to Oncocyte’s strategy," he added.

Progenetics CEO Yoav Manaster added that he believes DetermaRx "will gain significant physician and patient adoption" in the region.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.